Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails

Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet